Related Experiment Video
Updated: Jun 21, 2026

Anti-Nuclear Antibody Screening Using HEp-2 Cells
Published on: June 23, 2014
Anti-citrullinated protein antibody and rheumatoid factor in patients with end-stage renal disease
Zeljko Romic1, Adriana Unic, Lovorka Derek
1Clinical Department for Laboratory Diagnostic, Dubrava University Hospital, Zagreb, Croatia.
Background:
Patients with end-stage renal disease (ESRD) and on hemodialysis (HD) are at increased risk for developing rheumatoid arthritis (RA), as a result of defective immunity. Our aim was to examine if ESRD and the length of HD treatment impact the clinical utility of antibodies to cyclic citrullinated peptides (anti-CCP) and rheumatoid factor (RF) as diagnostic tools for RA.
Methods:
We included 94 subjects in our study: 37 healthy volunteers and 57 patients with ESRD who had been undergoing HD for 1-12 years, and without confirmed RA. In order to test our hypothesis, we measured and correlated anti-CCP and RF as laboratory markers of RA.
Results:
Our study showed that there is no significant difference between values for anti-CCP (p=0.11) and RF (p=0.98) in control subjects as well as in patients undergoing HD, regardless of the length of time that patients had been undergoing HD treatment.
Conclusions:
Our study indicates that HD does not impair the specificity of anti-CCP and RF for RA in patients where the disease has not yet developed. Future prospective studies may show whether there is any use in determinating RF, and especially anti-CCP, as early predictors of RA in patients with ESRD who are at greater risk of developing this condition.
Related Concept Videos
Chronic Kidney Disease III: Interprofessional Care
Chronic Kidney Disease I: Introduction
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Nephrotic Syndrome II : Assessment and Medical Management
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Antihypertensive Drugs: Direct Renin Inhibitors
